Australia markets closed

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
65.39+1.54 (+2.41%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close63.85
Open64.01
Bid0.00 x 1100
Ask0.00 x 800
Day's range62.19 - 65.79
52-week range25.31 - 141.01
Volume532,311
Avg. volume1,596,880
Market cap8.33B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Vir Biotechnology and GlaxoSmithKline Expand Their Partnership
    Motley Fool

    Vir Biotechnology and GlaxoSmithKline Expand Their Partnership

    Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) have gone from dating to a full-blown relationship in under a year. As part of the deal, GlaxoSmithKline took a $250 million stake in Vir. The giant British drugmaker must have liked what it saw in the American biotech because it is expanding its relationship with Vir to include treatments for influenza.

  • Why Vir Biotechnology Stock Is Higher Today
    Motley Fool

    Why Vir Biotechnology Stock Is Higher Today

    Shares of Vir Biotechnology (NASDAQ: VIR) were 12.6% higher as of 12:47 p.m. EST on Wednesday. The big gain came after Vir and GlaxoSmithKline (NYSE: GSK) announced that they're expanding their collaboration to include the development of therapies targeting influenza and other respiratory viruses. Last year, Vir and GlaxoSmithKline teamed up to develop therapies targeting coronaviruses, including the one that causes COVID-19.

  • Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen
    Zacks

    Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen

    Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.